Stock Analysis

Bintai Kinden Corporation Berhad Second Quarter 2025 Earnings: RM0.002 loss per share (vs RM0.007 loss in 2Q 2024)

KLSE:BINTAI
Source: Shutterstock

Bintai Kinden Corporation Berhad (KLSE:BINTAI) Second Quarter 2025 Results

Key Financial Results

  • Revenue: RM4.89m (down 26% from 2Q 2024).
  • Net loss: RM3.08m (loss narrowed by 49% from 2Q 2024).
  • RM0.002 loss per share (improved from RM0.007 loss in 2Q 2024).
earnings-and-revenue-history
KLSE:BINTAI Earnings and Revenue History November 22nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bintai Kinden Corporation Berhad's share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for Bintai Kinden Corporation Berhad (1 can't be ignored!) that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Bintai Kinden Corporation Berhad might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KLSE:BINTAI

Bintai Kinden Corporation Berhad

An investment holding company, provides specialized mechanical and electrical engineering services in South-East Asia, China, and the Arabian Gulf region.

Slight with acceptable track record.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor